Literature DB >> 29270332

Alagille syndrome: Genetics and Functional Models.

Melissa A Gilbert1, Nancy B Spinner1.   

Abstract

PURPOSE OF REVIEW: We review the genetics of the autosomal dominant, multi-system disorder, Alagille syndrome and provide a summary on how current functional models and emerging biotechnologies are equipped to guide scientists towards novel therapies. The importance of haploinsufficiency as a disease mechanism will be underscored throughout this discussion. RECENT
FINDINGS: Alagille syndrome, a human disorder affecting the liver, heart, vasculature, kidney, and other systems, is caused by mutations in the Notch signaling pathway ligand, Jagged1 (JAG1) or the receptor, NOTCH2. Current advances in animal modeling, in vitro cell culture, and human induced pluripotent stem cells, provide new opportunities in which to study disease mechanisms and manifestations.
SUMMARY: We anticipate that the availability of innovative functional models will allow scientists to test new gene therapies or small molecule treatments in physiologically-relevant systems. With these advances, we look forward to the development of new methods to help Alagille syndrome patients.

Entities:  

Keywords:  Alagille syndrome; Jagged1; Notch2; gene therapy; haploinsufficiency; liver disease

Year:  2017        PMID: 29270332      PMCID: PMC5736143          DOI: 10.1007/s40139-017-0144-8

Source DB:  PubMed          Journal:  Curr Pathobiol Rep        ISSN: 2167-485X


  62 in total

Review 1.  Alagille syndrome: pathogenesis, diagnosis and management.

Authors:  Peter D Turnpenny; Sian Ellard
Journal:  Eur J Hum Genet       Date:  2011-09-21       Impact factor: 4.246

2.  Regulation of mammalian Notch signaling and embryonic development by the protein O-glucosyltransferase Rumi.

Authors:  Rodrigo Fernandez-Valdivia; Hideyuki Takeuchi; Amin Samarghandi; Mario Lopez; Jessica Leonardi; Robert S Haltiwanger; Hamed Jafar-Nejad
Journal:  Development       Date:  2011-04-13       Impact factor: 6.868

3.  JAG1 mutations are found in approximately one third of patients presenting with only one or two clinical features of Alagille syndrome.

Authors:  K Guegan; K Stals; M Day; P Turnpenny; S Ellard
Journal:  Clin Genet       Date:  2011-07-31       Impact factor: 4.438

4.  NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway.

Authors:  Ryan McDaniell; Daniel M Warthen; Pedro A Sanchez-Lara; Athma Pai; Ian D Krantz; David A Piccoli; Nancy B Spinner
Journal:  Am J Hum Genet       Date:  2006-05-10       Impact factor: 11.025

Review 5.  Emerging roles of Notch signaling in liver disease.

Authors:  Fabian Geisler; Mario Strazzabosco
Journal:  Hepatology       Date:  2014-09-19       Impact factor: 17.425

6.  Bile duct proliferation in Jag1/fringe heterozygous mice identifies candidate modifiers of the Alagille syndrome hepatic phenotype.

Authors:  Matthew J Ryan; Christina Bales; Anthony Nelson; Dorian M Gonzalez; Lara Underkoffler; Michelle Segalov; Jeanne Wilson-Rawls; Susan E Cole; Jennifer L Moran; Pierre Russo; Nancy B Spinner; Kenro Kusumi; Kathleen M Loomes
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

7.  Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells.

Authors:  Ana M Crane; Philipp Kramer; Jacquelin H Bui; Wook Joon Chung; Xuan Shirley Li; Manuel L Gonzalez-Garay; Finn Hawkins; Wei Liao; Daniela Mora; Sangbum Choi; Jianbin Wang; Helena C Sun; David E Paschon; Dmitry Y Guschin; Philip D Gregory; Darrell N Kotton; Michael C Holmes; Eric J Sorscher; Brian R Davis
Journal:  Stem Cell Reports       Date:  2015-03-12       Impact factor: 7.765

Review 8.  Alagille syndrome: clinical perspectives.

Authors:  Maha Saleh; Binita M Kamath; David Chitayat
Journal:  Appl Clin Genet       Date:  2016-06-30

9.  Upregulating endogenous genes by an RNA-programmable artificial transactivator.

Authors:  Cristina Fimiani; Elisa Goina; Antonello Mallamaci
Journal:  Nucleic Acids Res       Date:  2015-07-07       Impact factor: 16.971

10.  RNA-guided gene activation by CRISPR-Cas9-based transcription factors.

Authors:  Pablo Perez-Pinera; D Dewran Kocak; Christopher M Vockley; Andrew F Adler; Ami M Kabadi; Lauren R Polstein; Pratiksha I Thakore; Katherine A Glass; David G Ousterout; Kam W Leong; Farshid Guilak; Gregory E Crawford; Timothy E Reddy; Charles A Gersbach
Journal:  Nat Methods       Date:  2013-07-25       Impact factor: 28.547

View more
  9 in total

1.  Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.

Authors:  Joshua M Adams; Kari A Huppert; Eumenia C Castro; Mario F Lopez; Nima Niknejad; Sanjay Subramanian; Neda Zarrin-Khameh; Milton J Finegold; Stacey S Huppert; Hamed Jafar-Nejad
Journal:  Hepatology       Date:  2020-01-24       Impact factor: 17.425

2.  Functional Studies of Genetic Variants Associated with Human Diseases in Notch Signaling-Related Genes Using Drosophila.

Authors:  Sheng-An Yang; Jose L Salazar; David Li-Kroeger; Shinya Yamamoto
Journal:  Methods Mol Biol       Date:  2022

3.  A boy with Alagille syndrome coexisting with mid-aortic syndrome and renovascular hypertension.

Authors:  Koji Yokoyama; Takaomi Minami; Mitsuru Seki; Yuko Okada; Hideki Kumagai; Takanori Yamagata
Journal:  J Cardiol Cases       Date:  2019-09-27

Review 4.  Cholangiopathies - Towards a molecular understanding.

Authors:  Paul K H Tam; Rachel S Yiu; Urban Lendahl; Emma R Andersson
Journal:  EBioMedicine       Date:  2018-09-17       Impact factor: 8.143

5.  Alagille syndrome mutation update: Comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification.

Authors:  Melissa A Gilbert; Robert C Bauer; Ramakrishnan Rajagopalan; Christopher M Grochowski; Grace Chao; Deborah McEldrew; James A Nassur; Elizabeth B Rand; Bryan L Krock; Binita M Kamath; Ian D Krantz; David A Piccoli; Kathleen M Loomes; Nancy B Spinner
Journal:  Hum Mutat       Date:  2019-08-26       Impact factor: 4.878

Review 6.  The Roles of Notch Signaling in Liver Development and Disease.

Authors:  Joshua M Adams; Hamed Jafar-Nejad
Journal:  Biomolecules       Date:  2019-10-14

7.  A Drosophila Su(H) model of Adams-Oliver Syndrome reveals cofactor titration as a mechanism underlying developmental defects.

Authors:  Ellen K Gagliani; Lisa M Gutzwiller; Yi Kuang; Yoshinobu Odaka; Phillipp Hoffmeister; Stefanie Hauff; Aleksandra Turkiewicz; Emily Harding-Theobald; Patrick J Dolph; Tilman Borggrefe; Franz Oswald; Brian Gebelein; Rhett A Kovall
Journal:  PLoS Genet       Date:  2022-08-11       Impact factor: 6.020

8.  Dominant mutations of the Notch ligand Jagged1 cause peripheral neuropathy.

Authors:  Jeremy M Sullivan; William W Motley; Janel O Johnson; William H Aisenberg; Katherine L Marshall; Katy Es Barwick; Lingling Kong; Jennifer S Huh; Pamela C Saavedra-Rivera; Meriel M McEntagart; Marie-Helene Marion; Lucy A Hicklin; Hamid Modarres; Emma L Baple; Mohamed H Farah; Aamir R Zuberi; Cathleen M Lutz; Rachelle Gaudet; Bryan J Traynor; Andrew H Crosby; Charlotte J Sumner
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

9.  JAGGED1 stimulates cranial neural crest cell osteoblast commitment pathways and bone regeneration independent of canonical NOTCH signaling.

Authors:  Archana Kamalakar; Jay M McKinney; Daniel Salinas Duron; Angelica M Amanso; Samir A Ballestas; Hicham Drissi; Nick J Willett; Pallavi Bhattaram; Andrés J García; Levi B Wood; Steven L Goudy
Journal:  Bone       Date:  2020-09-25       Impact factor: 4.626

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.